Florida Cancer Specialists & Research Institute participates in the Global Gathering to share advances in cancer pharmacy services

Florida Cancer Specialists & Research Institute participates in the Global Gathering to share advances in cancer pharmacy services

FCS doctors and leaders shared the latest advances in cancer pharmacy operations and dispensing practices at the National Community Oncology Dispensing Association (NCODA) Spring 2022 Forum held last month in Atlanta.

FCS President and MD Michael Diaz, MD; Nathan H. Walcker, managing director of FCS; FCS medical oncologist Michel Velez, MD; Senior Director of Pharmaceutical Services at FCS Ray Bailey, Bpharm, RPh; FCS Clinical Oncology Pharmacist Chris Elder, PharmD, BCOP; Director of Clinical Services of Pharmacy for RXTOGO Pharmacy Natasha Khrystolubova, RPh, Bpharm, BCOP; FCS Associate Director of Pharmacy Services Kara Sammons, CPhT; FCS Prior Authorization Supervisor Amy Terhune, CPhT; FCS medical oncologist Michel Velez

Fort Myers, Florida, May 06, 2022 (GLOBE NEWSWIRE) – Doctors and leaders from the Florida Cancer Specialists & Research Institute (FCS) shared the latest advances in cancer pharmacy operations and dispensing practices to the National Community Oncology Dispensing Association (NCODA ) 2022 The Spring Forum held last month in Atlanta. The multi-day meeting of global cancer care professionals delved into new opportunities to increase the value of pharmaceutical services within medically integrated cancer practices.

Several discussions involved the leaders of Rx To Go, FCS’s in-house oral oncolytic pharmacy, which works exclusively with the study’s physicians, physicians, and patients across the state to provide timely dispensing and convenient home delivery of medications. Rx To Go’s experienced team of pharmacists, technicians and staff offers an advanced level of personalized care and disease management so that patients achieve optimal clinical outcomes.

A keynote presentation by FCS medical oncologist Michel Velez, MD was titled: Tukysa (tucatinib) A treatment option for patients with HER2 + metastatic breast cancer

As speakers during workshops and interactive discussions they were:

  • Ray Bailey, BPharm, RPh, Senior Director of Pharmaceutical Services at FCS – NCODA Nonprofit Partner Update and Donor Story: Be the Match

  • Chris Elder, PharmD, BCOP, FCS Clinical Oncology Pharmacist – Implementing Positive Quality Interventions: Consistent Clinical Standards and NCODA Resources

  • Natasha Khrystolubova, RPh, BPharm, BCOP, Director of Pharmacy Clinical Services for RXTOGO Pharmacy, and Amy Terhune, CPhT, FCS Prior Authorization Supervisor – Prior authorization procedures and multiple appeal: How to create a stronger appeal

  • Kara Sammons, CPhT, Associate Director of Pharmacy Services at FCS – NCODA Center of Excellence Medically Integrated Pharmacy Accreditation

Michael Diaz, MD, FCS President and Managing Physician, said, “Given the continuing rapid rise of oral oncolytic drugs in the treatment of all forms of cancer, we are proud to partner with NCODA to share and learn with our peers to help. improve pharmacy operations and ultimately patient outcomes around the world. “

“Our Rx To Go team continues to meet and exceed best practice standards for oral oncolytic pharmacy services and quality improvement initiatives,” said Nathan H. Walcker, CEO of FCS, adding that Rx To Go is accredited by URAC for Specialty Pharmacy, Health Care Accreditation Commission (ACHC) with oncology distinction and doubly accredited by the National Association of Boards of Pharmacy® (NABP®) for the specialized pharmacy. FCS is also NABP accredited for digital pharmacy practice.

NCODA is a globally recognized non-profit organization dedicated to creating a patient-centric and medically integrated community of healthcare professionals whose goal is to innovate continuity of cancer care so that every patient receives the maximum benefit from cancer treatment.

###

Information on Florida cancer specialists and the research institute
Recognized by the American Society of Clinical Oncology (ASCO) with a National Clinical Trials Participation Award, Florida Cancer Specialists & Research Institute (FCS) gives patients access to more clinical trials than any private cancer practice in Florida. Over the past 5 years, most of the new cancer drugs approved for use in the United States have been studied in clinical trials with the participation of Florida Cancer Specialists. * Trained in prestigious medical schools and research institutes such as Duke, Stanford, Harvard, Emory, MD Anderson and Memorial Sloan Kettering, our physicians are consistently ranked nationally as Top Doctors by US News & World Report.

Florida Cancer Specialists have built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research, cutting-edge technologies and advanced treatments, including targeted therapies, genomic treatment, and immunotherapy. Our values ​​are embodied by our exceptional team of highly trained and dedicated doctors, clinicians and staff.

* Before approval

Attached

CONTACT: Michelle Robey Florida Cancer Specialists & Research Institute 813-767-9398 Michelle.Robey@FLCancer.com Jen Bradley Florida Cancer Specialists & Research Institute 847-280-1740 Jennifer.Bradley@FLCancer.com

Leave a Comment

Your email address will not be published.